Recombinant Human Oxidized Low-Density Lipoprotein Receptor 1 (OLR1) Protein (His)

Beta LifeScience SKU/CAT #: BLC-08558P
Greater than 90% as determined by SDS-PAGE.
Greater than 90% as determined by SDS-PAGE.

Recombinant Human Oxidized Low-Density Lipoprotein Receptor 1 (OLR1) Protein (His)

Beta LifeScience SKU/CAT #: BLC-08558P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Oxidized Low-Density Lipoprotein Receptor 1 (OLR1) Protein (His) is produced by our E.coli expression system. This is a extracellular protein.
Purity Greater than 90% as determined by SDS-PAGE.
Uniprotkb P78380
Target Symbol OLR1
Synonyms C-type lectin domain family 8 member A; CLEC8A; hLOX 1; hLOX-1; Lectin like oxidized LDL receptor 1; Lectin like oxLDL receptor 1; Lectin type oxidized LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; Lectin-type oxidized LDL receptor 1; low density lipoprotein oxidized, receptor 1; LOX-1; LOXIN; Olr1; OLR1_HUMAN; Ox LDL receptor 1; Ox-LDL receptor 1; Oxidised low density lipoprotein (lectin like) receptor 1; Oxidized low density lipoprotein receptor 1; Oxidized low density lipoprotein receptor 1 soluble form; Oxidized low-density lipoprotein receptor 1; OxLDL receptor 1 ; SCARE1; Scavenger receptor class E, member 1; SLOX1; soluble form; SR-EI
Species Homo sapiens (Human)
Expression System E.coli
Tag N-6His
Target Protein Sequence MQLSQVSDLLTQEQANLTHQKKKLEGQISARQQAEEASQESENELKEMIETLARKLNEKSKEQMELHHQNLNLQETLKRVANCSAPCPQDWIWHGENCYLFSSGSFNWEKSQEKCLSLDAKLLKINSTADLDFIQQAISYSSFPFWMGLSRRNPSYPWLWEDGSPLMPHLFRVRGAVSQTYPSGTCAYIQRGAVYAENCILAAFSICQKKANLRAQ
Expression Range 58-273aa
Protein Length Extracellular Domain
Mol. Weight 28.7kDa
Research Area Cardiovascular
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
Subcellular Location Cell membrane; Lipid-anchor. Cell membrane; Single-pass type II membrane protein. Membrane raft. Secreted. Note=A secreted form also exists. Localization to membrane rafts requires palmitoylation.
Database References

HGNC: 8133

OMIM: 602601

KEGG: hsa:4973

STRING: 9606.ENSP00000309124

UniGene: PMID: 28345638

  • LOX-1(+) CD15(+) polymorphonuclear myeloid-derived suppressor cells were elevated in hepatocellular carcinoma patients and suppressed T cell proliferation through ROS/Arg I pathway induced by ER stress. PMID: 29211299
  • High LOX-1 ligand activity as a risk factor for ischemic stroke. PMID: 28442661
  • The analysis also revealed that OLR1 is not required for the transcriptional regulation induced by oxidized PAPC but interestingly, OLR1 knockdown affected expression of CNN2, HMRR, ITGB6 and KIF20A, all genes governing cell proliferation and motility. PMID: 29103984
  • Data show that oxidized low density lipoprotein receptor 1 (LOX-1) is overexpressed in prostate cancer cells. PMID: 29107109
  • expression significantly higher in the arterial wall of epicardial coronary arteries compared to intramyocardial coronary arteries PMID: 29448251
  • let7g exerts a LOX1independent antiaging effect on endothelial cells. PMID: 29393358
  • high LOX-1 expression in pancreatic cancer tissues is indicative for the occurrence of lymph node metastases, high TNM stages and a poor prognosis. PMID: 29168159
  • lincRNAp21 is a major mediator of oxLDLinduced apoptosis and expression of LOX1 in human vascular endothelial cells, and acts via activation of PKCdelta. PMID: 28983628
  • this study shows that LOX-1 is involved in IL-1beta production and extracellular matrix breakdown in dental peri-implantitis PMID: 28898769
  • Results showed that the scFv with N-terminal fusing peptides proteins demonstrated increased LOX-1-binding activity without decrease in stability. These findings will help increase the application efficacy of LOX-1 targeting scFv in LOX-1-based therapy PMID: 29094051
  • The serum sLOX-1 level was higher in patients with large artery atherosclerotic stroke, and it was an independent predictor of functional outcome in patients with large artery atherosclerotic ischemic stroke. PMID: 27967338
  • LOX-1 has a role in atherogenesis and tumorigenesis as a potential link in these diseases [review] PMID: 29462603
  • the rs1050283 T allele of LOX-1 is strongly associated with an increased risk for atherosclerotic cerebral infarction in a Chinese population, which also affects levels of LOX-1 and sLOX-1 PMID: 27840386
  • data revealed that miR-let-7g exhibits anti-atherosclerotic activity, at least partially by targeting the LOX-1 signaling pathway. PMID: 28535009
  • High LOX1 expression is associated with colorectal cancer. PMID: 26895376
  • Increased LOX-1 expression in endothelial cells is potentially involved in the pathogenesis of sickle cell disease vasculopathy PMID: 27519944
  • LOX-1 signalling and the crucial role of cytokines PMID: 28860004
  • High OLR1 expression is associated with breast cancer. PMID: 28844714
  • Multiple classical molecular dynamics simulations have been applied to the human LOX-1 receptor to clarify the role of the Trp150Ala mutation in the loss of binding activity. Results indicate that the substitution of this crucial residue, located at the dimer interface, markedly disrupts the wild-type receptor dynamics PMID: 28657156
  • Carrying the C allele of the rs11053646 variant of the OLR1 gene was associated with an increased risk of CAD in heterozygous adult patients with FH, and this risk could be even greater in smokers as well as in younger patients. PMID: 28941610
  • Berberine could prevent the oxLDL and TNFalpha - induced LOX1 expression and oxidative stress, key events that lead to NOX, MAPK/Erk1/2 and NF-kappaB activation linked to endothelial dysfunction. PMID: 28511903
  • Individuals >/=30 years old with abdominal obesity presented lower Lox1 levels than patients >/=30 years old without abdominal obesity. PMID: 27525284
  • These studies suggest that activation of LOX-1 expression occurs through binding of the chlamydial glycan and provides one mechanism by which Chlamydia pneumoniae infection could play a role in the pathogenesis of atherosclerosis. PMID: 23821487
  • Elevated LOX1 is Associated with Acute Stroke. PMID: 27025681
  • Xanthine oxidase induces foam cell formation in large part through activation of LOX-1 - NLRP3 pathway in both vascular smooth muscle cells and THP-1 cells. PMID: 28084571
  • show that MiR-590-5p inhibits angiogenesis by targeting LOX-1 and suppressing redox-sensitive signals PMID: 26932825
  • OLR1 rs1050286 SNP may contribute to modify OLR1 susceptibility to acute myocardial infarction and coronary artery diseases. PMID: 26542080
  • Serum sLOX-1 level was significantly lower in the restless legs syndrome patient group compared to controls. PMID: 27546362
  • The mechanistic link between miR-590-5p and LOX-1:miR-590-5p downregulation led to LOX-1 upregulation in endothelial cells. PMID: 26906623
  • Serum LAB was associated with an increased carotid IMT in Japanese men, especially those with hypercholesterolemia PMID: 26892134
  • the current meta-analysis highlighted that variant allele of OLR1 rs11053646 G > C and PCSK9 rs505151 A > G may contribute to the susceptibility risk of ischemic stroke. PMID: 26666837
  • Silencing of LOX-1 gene expression abolished ox-LDL induced effects in cell viability, reactive oxygen species generation and gene expression. PMID: 26510581
  • both the 501>C single nucleotide polymorphisms in the LOX1 gene and the serum LOX1 level may be used to predict the development of left ventricular hypertrophy among essential hypertension patients. PMID: 24480971
  • for our Turkish sample group, LOX-1 30UTR188C/T and K167N polymorphisms may not be involved in susceptibility to GDM [gestational diabetes mellitus ] PMID: 26296941
  • Cholesterol depletion triggers the release of LOX-1 in exosomes as a full-length transmembrane isoform and as a truncated ectodomain soluble fragment. PMID: 26495844
  • Interaction between Lox-1, C-reactive protein and oxidized LDL play role in the pathogenesis of atherosclerosis. PMID: 26607724
  • OLR1 is a novel molecular link between the proliferative and inflammatory responses of vascular smooth muscle cells. PMID: 26305474
  • Ginkgo biloba extract inhibits oxLDL-induced matrix metalloproteinase activation by the modulation of the LOX1-regulated signaling pathway in human umbilical vein endothelial cells. PMID: 25080882
  • Data show that the interplay between the two TNF receptors (TNFR1 and TNFR2) was apparent in the expression pattern of lectin-type oxidized LDL receptor 1 (LOX-1) in response to TNF-alpha. PMID: 25416967
  • The serum LOX-1 levels were significantly higher in NAFLD patients than in healthy controls. PMID: 26185381
  • Low shear stress is a regulator of autophagy and LOX-1 plays an important role in shear stress induced autophagy. PMID: 25697875
  • results showed higher expression of HSP70 and LOX-1 in the placental tissues of pre-eclampsia patients which represent the possible contribution of these molecules in the disease pathogenesis. PMID: 24786389
  • Elevated plasma sLOX-1 level on admission independently predicts long-term all-cause mortality and MACE after STEMI. PMID: 25746549
  • biomarker for determining early endothelial damage in hypertension, especially in white coat hypertension PMID: 25007999
  • LOX-1 activation by oxLDL is an important event that enhances tumor angiogenesis PMID: 25170920
  • LOX-1 is the receptor that mediates oxidized LDL activity in vascular endothelial cells.Activation of LOX-1 causes endothelial dysfunction and vascular lipid deposition. PMID: 25463747
  • Our data indicate a new direction for LOX-1 regulation by the modulation of the PKCbeta/NAPDH oxidase/SIRT1/HSF1 mechanism PMID: 25982096
  • The present study showed that circulating soluble LOX-1 originates from coronary circulation and soluble LOX-1 and LOX-1 index are useful biomarkers for acute coronary syndrome. PMID: 24895597
  • Meta-analysis results showed that the +1073 C/T polymorphism in ORL1 decreased the risk of Alzheimer's disease. This allele was predicted to affect the binding site of many miRNAs explaining the relationship between the +1073 C/T variant and the disease. PMID: 25501227
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed